Financial Performance - The company's revenue for Q3 2025 reached ¥127,428,922.73, an increase of 20.87% compared to the same period last year[4]. - The total profit for the period was ¥56,933,271.87, reflecting a growth of 14.24% year-over-year[4]. - The net profit attributable to shareholders was ¥49,072,717.48, up by 14.51% from the previous year[4]. - The net profit for the first three quarters of 2025 reached CNY 169,893,968.80, an increase from CNY 161,669,487.31 in the same period of 2024, representing a growth of approximately 13.5%[20]. - Operating profit for the same period was CNY 198,450,191.52, compared to CNY 189,081,288.34 in 2024, indicating a year-over-year increase of about 7.3%[20]. - The company reported sales revenue from goods and services of CNY 416,771,775.69, compared to CNY 406,134,600.13 in the previous year, reflecting a growth of about 2.0%[22]. - The total comprehensive income for the period was CNY 169,893,968.80, compared to CNY 161,669,487.31 in 2024, showing an increase of approximately 5.4%[21]. Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date was ¥133,936,717.80, showing a decline of 20.12% compared to the previous year[4]. - Cash flow from operating activities generated a net amount of CNY 133,936,717.80, down from CNY 167,668,964.18 in the previous year, reflecting a decrease of approximately 20.2%[23]. - The cash flow from financing activities showed a net outflow of CNY 235,851,204.77, contrasting with a net inflow of CNY 463,327,854.95 in the same period last year[24]. - The company ended the period with cash and cash equivalents of CNY 412,565,553.40, down from CNY 552,013,365.43 at the end of the previous year, a decrease of about 25.3%[24]. - Cash and cash equivalents as of September 30, 2025, amounted to ¥734,868,351.75, down from ¥883,430,759.69 at the end of 2024[14]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,307,629,743.16, a decrease of 6.76% from the end of the previous year[5]. - Total assets decreased from ¥1,402,448,475.00 in 2024 to ¥1,307,629,743.16 in 2025, a decline of 6.8%[15]. - Total liabilities increased from ¥168,213,793.02 in 2024 to ¥253,534,342.28 in 2025, reflecting a rise of 50.8%[16]. - Shareholders' equity attributable to the company was ¥1,054,095,400.88, down 14.60% compared to the previous year[5]. - Shareholders' equity decreased from ¥1,234,234,681.98 in 2024 to ¥1,054,095,400.88 in 2025, a decline of 14.6%[16]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 13,356[10]. - The largest shareholder, 运佳远东有限公司, holds 58.59% of the shares, totaling 94,080,000 shares[11]. Operating Costs and Expenses - Total operating revenue for the first three quarters of 2025 reached ¥397,218,590.16, an increase of 8.5% compared to ¥367,213,945.74 in the same period of 2024[19]. - Total operating costs for the first three quarters of 2025 were ¥198,287,211.92, up from ¥179,224,454.99 in 2024, reflecting a growth of 10.5%[19]. - Operating costs specifically increased from ¥125,382,134.24 in 2024 to ¥132,124,401.09 in 2025, indicating a rise of 5.9%[19]. - Research and development expenses decreased to CNY 9,124,036.50 from CNY 10,672,621.35, a reduction of approximately 14.5%[20]. Government Subsidies - The company received government subsidies amounting to ¥54,924.12 during the period, contributing to its non-recurring gains[7]. Earnings Per Share - Basic earnings per share for the period stood at ¥0.31, with a year-to-date figure of ¥1.06, down 17.19%[5]. - The basic earnings per share for the current period was CNY 1.06, down from CNY 1.28 in the previous year, indicating a decline of about 17.2%[21].
小方制药(603207) - 2025 Q3 - 季度财报